TGF-β: A Balancing Act

References

• McCartney-Francis N. L., Wahl S. M. Transforming growth factor β: a matter of life and death. J. Leukoc. Biol. 1994; 55: 401–409
   PubMed Web of Science ®Google Scholar
• Roberts A. B., Sporn M. B. Transforming growth factor-β. The Molecular and Cellular Biology of Wound Repair Clark. Plenum Press, RAF New York 1996; 275–308
   Google Scholar
• Lawrence D. A. Transforming growth factor-β: a general review. Eur. Cytokine Netw. 1996; 7: 363–374
   PubMed Web of Science ®Google Scholar
• Shah M., Foreman D. M., Ferguson M. W.J. Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 1995; 108: 15–17
   Google Scholar
• Nunes I., Munger J. S., Harpel J. G., Nagano Y., Shapiro R. L., Gleizes P.-E., Rifkin D. B. Structure and activation of the large latent transforming growth factor-β complex. Intl. J. Obes. 1996; 20: S4–S8
   Google Scholar
• Miyazono K., Ichijo H., Heldin C.-H. Transforming growth factor-β: latent forms, binding proteins and receptors. Growth Factors 1993; 8: 11–22
   PubMed Web of Science ®Google Scholar
• Grainger D. J., Kemp P. R., Liu A. C., Lawn R. M., Metcalfe J. C. Activation of transforming growth factor-β is inhibited in transgenic apolipoprotein(a) mice. Nature 1994; 370: 460–462
   PubMed Web of Science ®Google Scholar
• Grainger D. J., Kemp P. R., Metcalfe J. C., Liu A. C., Lawn R. M., Grace A. A., Williams N. R., Schofield P. M., Chauhan A. Active transforming growth factor β is depressed five fold in patients with coronary artery disease. Nature Med. 1995; 1: 74–79
   PubMed Web of Science ®Google Scholar
• Altman D. J., Schneider S. L., Thompson D. A., Cheng H. L., Tomasi T. B. A transforming growth factor-β2 (TGF-β2)-like immunosuppressive factor in amniotic fluid and localization of TGF-β2 mRNA in the pregnant uterus. J. Exp. Med. 1990; 172: 1391–1401
   PubMed Web of Science ®Google Scholar
• Schultz-Cherry S., Chen H., Mosher D. F., Misenheimer T. M., Krutzch H. C., Roberts D. D., Murphy-Ulrich J. E. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 1995; 270: 7304–7310
   PubMed Web of Science ®Google Scholar
• Kim S.-J., Romeo D., Yoo Y. D., Park K. Transforming growth factor-β expression in normal and pathological conditions. Harm. Res. 1994; 42: 5–8
   PubMedGoogle Scholar
• Yoo Y. D., Ueda H., Park K., Flanders K. C., Lee Y. I., Jay G., Kim S.-J. Regulation of transforming growth factor-β1 expression by the hepatitis B virus (HBV) X transactivator. J. Clin. Invest. 1996; 97: 388–395
   PubMed Web of Science ®Google Scholar
• Yoo Y. D., Chiou C. J., Choi K. S., Yi Y., Michelson S., Kim S., Hayward G. S., Kim S. J. The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta-1 gene through an Egr-1 binding site. J. Virol. 1996; 70: 7062–7070
   PubMedGoogle Scholar
• Dey B. R., Sukhatme V. P., Roberts A. B., Sporn M. B., Rauscher I F.J., II, Kim S.-J. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Mol. Endocrinol. 1994; 8: 595–602
   PubMed Web of Science ®Google Scholar
• Kim S. J., Park K., Rudkin B. B., Dey B. R., Sporn M. B., Roberts A. B. Nerve growth factor induces transcription of transforming growth factor-beta 1 through a specific promoter element in PC12 cells. J. Biol. Chem. 1994; 269: 3739–3744
   PubMed Web of Science ®Google Scholar
• Nørgaard P., Hougaard S., Poulsen H. S., Spang-Thomsen M. Transforming growth factor β and cancer. Cancer Treat. Rev. 1995; 21: 367–403
   PubMedGoogle Scholar
• Yingling J. M., Wang X.-F., Bassing C. H. Signaling by the transforming growth factor-β receptors. Biochim. Biophys. Acta. 1995; 1242: 115–136
   PubMed Web of Science ®Google Scholar
• López-Casillas F., Wrana J. L. and Massagué, J. Betaglycan presents ligand to the TGFβ signaling receptor. Cell 1993; 73: 1435–1444
   PubMed Web of Science ®Google Scholar
• Cheifetz S., Bellon T., Calés C., Vera S., Bemabeu C., Massagué J., Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J. Biol. Chem. 1992; 267: 19027–19030
   PubMed Web of Science ®Google Scholar
• Wrana J. L., Attisano L., Wieser R., Ventura F. and Massagué, J. Mechanism of activation of the TGF-β receptor. Nature 1994; 370: 341–347
   PubMed Web of Science ®Google Scholar
• Attisano L., Wrana J. L., Montalvo E. and Massagué, J. Activation of signaling by the activin receptor complex. Mol. Cell. Biol. 1996; 16: 1066–1073
   PubMed Web of Science ®Google Scholar
• Wieser R., Wrana J. L., Massague J. GS domain mutations that constitutively activate TβR-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 1995; 14: 2199–2208
   PubMedGoogle Scholar
• Wang T., Li B. Y., Danielson P. D., Shah P. C., Rockwell S., Lechleider R. J., Martin J., Manganaro T., Donahoe P. K. The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type I receptors. Cell 1996; 86: 435–444
   PubMed Web of Science ®Google Scholar
• Wang T., Danielson P. D., Li B., Shah P. C., Kim S. D., Donahoe P. K. p21 Ras farnesyltransferase-α subunit in TGFβ and activin signaling. Science 1996; 271: 1120–1122
   PubMed Web of Science ®Google Scholar
• Kawabata M., Inamura T., Miyazono K., Engel M. E., Moses H. L. Interaction of the transforming growth factor-β type I receptor with farnesyltransferase-α. J. Biol. Chem. 1995; 270: 29628–29631
   PubMedGoogle Scholar
• Chen R. H., Miettinen P. J., Maruoka E. M., Choy L., Derynck R. A WD-domain protein that is associated with, and phosphorylated by, the type II TGF-beta receptor. Nature 1995; 377: 548–552
   PubMedGoogle Scholar
• Ventura F., Liu F., Doody J. and Massagué, J. Interaction of transforming growth factor-β receptor I with farnesyl-protein transferase-α in yeast and mammalian cells. J. Biol. Chem. 1996; 271: 13931–13934
   PubMedGoogle Scholar
• Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., Taniguchi T., Nishida E., Matsumoto K. Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction. Science 1995; 270: 2008–2011
   PubMed Web of Science ®Google Scholar
• Massagué J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 1996; 85: 947–950
   PubMed Web of Science ®Google Scholar
• Zhang Y., Feng X. H., Wu R.-Y., Derynck R. Mad homologues synergize as effectors of the TGF-β response. Nature 1996; 383: 168–172
   PubMed Web of Science ®Google Scholar
• Macias-Silva M., Abdollah S., Hoodless P. A., Pirone R., Attisano L., Wrana J. L. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87: 1215–1224
   PubMed Web of Science ®Google Scholar
• Lagna G., Hata A., Hemmati-Brivanlou A., Massague J. Partnership between DPC4 and SMAD proteins in TGF-β signaling pathways. Nature 1996; 383: 832–836
   PubMed Web of Science ®Google Scholar
• Hahn S. A., Schutte M., Hogue A. T.M.S., Moskaluk C. A., da Costa L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H., Kern S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350–353
   PubMed Web of Science ®Google Scholar
• Liu F., Hata A., Baker J. C., Doody J., Cárcamo J., Harland R. M. and Massagué, J. A human MAD protein acting as a BMP—regulated transcriptional activator. Nature 1996; 381: 620–623
   PubMed Web of Science ®Google Scholar
• Roberts A. B., Sporn M. B. Differential expression of the TGF-β isoforms in embryogenesis suggests specific roles in developing and adult tissues. Mol. Reprod. Dev. 1992; 32: 91–98
   PubMed Web of Science ®Google Scholar
• Dickson M. C., Martin J. S., Cousins F. M., Kulkarni A. B., Karlsson S., Akhurst R. J. Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice. Development 1995; 121: 1845–1854
   PubMed Web of Science ®Google Scholar
• Bonyadi M., Rusholme S. A.B., Cousins F. M., Su H. C., Biron C. A., Farrall M., Akhurst R. J. Mapping of a major genetic modifier of embryonic lethality in TGFβ1 knockout mice. Nature Genet. 1997; 15: 207–211
   PubMedGoogle Scholar
• Oshima M., Oshima H., Taketo M. M. TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis. Devel. Biol. 1996; 179: 297–302
   PubMed Web of Science ®Google Scholar
• Letterio J. J., Geiser A. G., Kulkarni A. B., Roche N. S., Sporn M. B., Roberts A. B. Maternal rescue of transforming growth factor-β1 null mice. Science 1994; 264: 1936–1938
   PubMed Web of Science ®Google Scholar
• Diebold R. J., Eis M. J., Yin M., Ormsby I., Boivin G. P., Darrow Saffitz B. J.J.E., Doetschman T. Early-onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte mediated. Proc. Natl. Acad. Sci. USA 1995; 92: 12215–12219
   PubMed Web of Science ®Google Scholar
• Kaartinen V., Voncken J. W., Shuler C., Warburton D., Bu D., Heisterkamp N., Groffen J. Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial-mesenchymal interaction. Nature Genet. 1995; 11: 415–420
   PubMed Web of Science ®Google Scholar
• Proetzel G., Pawlowski S. A., Wiles M. V., Yin M., Boivin G. P., Howies P. N., Ding J., Ferguson M. W.J, Doetschman T. Transforming growth factor-β3 is required for secondary palate fusion. Nature Genet. 1995; 11: 409–414
   PubMed Web of Science ®Google Scholar
• Sellheyer K., Bickenbach J. R., Rothnagel J. A., Bundman D., Longley M. A., Krieg T., Roche N. S., Roberts A. B., Roop D. R. Inhibition of skin development by overexpression of transforming growth factor-β1 in the epidermis of transgenic mice. Proc. Natl. Acad. Sci. USA 1993; 90: 5237–5241
   PubMed Web of Science ®Google Scholar
• Cui W., Fowlis D. J., Cousins F. M., Duffie E., Bryson S., Balmain A., Akhurst R. J. Concerted action of TGF-β1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Devel. 1995; 9: 945–955
   PubMedGoogle Scholar
• Fowlis D. J., Cui W., Johnson S. A., Balmain A., Akhurst R. J. Altered epidermal cell growth control in vivo by inducible expression of transforming growth factor β1 in the skin of transgenic mice. Cell Growth Diff. 1996; 7: 679–687
   PubMedGoogle Scholar
• Jhappan C., Geiser A. G., Kordon E. C., Bagheri D., Hennighausen L., Roberts A. B., Smith G. H., Merlino G. Targeting expression of a transforming growth factor-β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation. EMBO J. 1993; 12: 1835–1845
   PubMedGoogle Scholar
• Pierce D. F., Jr, Johnson M. D., Matsui Y., Robinson S. D., Gold L. I., Purchio A. F., Daniel C. W., Hogan B. L.M., Moses H. L. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Devel. 1993; 7: 2308–2317
   PubMed Web of Science ®Google Scholar
• Lee M. S., Gu D., Feng L., Curriden S., Arnush M., Krahl T., Gurushanthaiah D., Wilson C., Loskutoff D. L., Fox H., Sarvetnick N. Accumulation of extracellular matrix and developmental dysregulation in the pancreas by transgenic production of transforming growth factor-β1. Am. J. Pathol. 1995; 147: 42–52
   PubMed Web of Science ®Google Scholar
• Sanvito F., Nichols A., Herrera P. L., Huarte J., Wohlwend A., Vassalli J.-D., Orci L. TGF-β1 overexpression in murine pancreas induces chronic pancreatitis and, together with TNF-α, triggers insulin-dependent diabetes. Biochem. Biophys. Res. Commun. 1995; 217: 1279–1288
   PubMedGoogle Scholar
• Wyss-Coray T., Feng L., Masliah E., Ruppe M. D., Lee H. S., Toggas S. M., Rockenstein E. M., Mucke L. Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-β1. Am. J. Pathol. 1995; 147: 53–67
   PubMed Web of Science ®Google Scholar
• Galbreath E., Kim S. J., Park K., Brenner M., Messing A. Overexpression of TGFβ1 in the central nervous system of transgenic mice results in hydrocephalus. J. Neuropathol. Exp. Neurol. 1995; 54: 339–349
   PubMedGoogle Scholar
• Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A. B., Sporn M. B., Thorgeirsson S. S. Hepatic expression of mature transforming growth factor-β1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA 1995; 92: 2572–2576
   PubMed Web of Science ®Google Scholar
• Zhou L., Dey C. R., Wert S. E., Whitsett J. A. Arrested lung morphogenesis in transgenic mice bearing an SP-C-TGF-beta 1 chimeric gene. Dev. Biol. 1996; 175: 227–238
   PubMed Web of Science ®Google Scholar
• Erlebacher A., Derynck R. Increased expression of TGF-β2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell. Biol. 1996; 132: 195–210
   PubMed Web of Science ®Google Scholar
• Alexandrow M. G., Moses H. L. Transforming growth factor β and cell cycle regulation. Cancer Research 1995; 55: 1452–1457
   PubMed Web of Science ®Google Scholar
• Schwarz J. K., Bassing C. H., Kovesdi I., Datto M. B., Blazing M., George S., Wang X.-F., Nevins J. R. Expression of the E2F1 transcription factor overcomes type β transforming growth factor-mediated growth suppression. Proc. Natl. Acad. Sci. USA 1995; 92: 483–487
   PubMed Web of Science ®Google Scholar
• Glick A. B., Kulkarni A. B., Tennenbaum T., Hennings H., Flanders K. C., O'Reilly M., Sporn M. B., Karlsson S., Yuspa S. H. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc. Natl. Acad. Sci. USA 1993; 90: 6076–6080
   PubMed Web of Science ®Google Scholar
• Markowitz S. D., Roberts A. B. Tumor suppressor activity of the TGF-β pathway in human cancers. Cyt. Growth Fact. Rev. 1996; 7: 93–102
   PubMedGoogle Scholar
• Sun L., Wu G., Willson J. K.V., Zborowska E., Yang J., Rajkarunanayake I., Wang J., Gentry L. E., Wang X., Brittain M. G. Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J. Biol. Chem. 1994; 269: 26449–26455
   PubMed Web of Science ®Google Scholar
• Wang J., Han W., Zborowska E., Liang J., Wang X., Willson J. K.V., Sun L., Brattain M. G. Reduced expression of transforming growth factor β type I receptor contributes to the malignancy of human colon carcinoma cells. J. Biol. Chem. 1996; 271: 17366–17371
   PubMed Web of Science ®Google Scholar
• Goyette M. C., Cho K., Fasching C. L., Levy D. B., Kinzler K. W., Paraskeva C., Vogelstein B., Stanbridge E. J. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol. Cell. Biol. 1992; 12: 1387–1395
   PubMed Web of Science ®Google Scholar
• Eppert K., Scherer S. W., Ozcelik H., Pirone R., Hoodless P., Kim H., Tsui L.-C, Bapat B., Gallinger S., Andrulis I. L., Thomsen G. H., Wrana J. L., Attisano L. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86: 543–552
   PubMed Web of Science ®Google Scholar
• Arteaga C. L., Coffey R. J., Jr., Dugger T. C., McCutchen C. M., Moses H. L., Lyons R. M. Growth stimulation of human breast cancer cells with anti-transforming growth factor β antibodies: evidence for negative autocrine regulation by transforming growth factor β. Cell Growth & Differ. 1990; 1: 367–374
   PubMedGoogle Scholar
• Wu S., Theodorescu D., Kerbel R., Willson J. K.V., Mulder K. M., Humphrey L. E., Brattain M. G. TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J. Cell. Biol. 1992; 116: 187–196
   PubMed Web of Science ®Google Scholar
• Pierce D. F., Gorska A. E., Chytil A., Meise K. S., Page D. L., Coffey R. L., Jr, Moses H. L. Mammary tumor suppression by transforming growth factor β1 transgene expression. Proc. Nail. Acad. Sci. USA 1995; 92: 4254–4258
   PubMed Web of Science ®Google Scholar
• Cui W., Fowlis D. J., Bryson S., Duffie E., Ireland H., Balmain A., Akhurst R. J. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996; 86: 531–542
   PubMed Web of Science ®Google Scholar
• Glick A. B., Lee M. M., Darwiche N., Kulkarni A. B., Karlsson S., Yuspa S. H. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Devel. 1994; 8: 2429–2440
   PubMed Web of Science ®Google Scholar
• Glick A. B., Weinberg W. C., Wu I. H., Quan W., Yuspa S. H. Transforming growth factor beta 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res. 1996; 56: 3645–3650
   PubMedGoogle Scholar
• Christ M., McCartney-Francis N. L., Kulkarni A. B., Ward J. M., Mizel D. E., Mackall C. L., Gress R. E., Hines K. L., Tian H., Karlsson S., Wahl S. M. Immune dysregulation in TGF-β1-deficient mice. J. Immunol. 1994; 153: 1936–1946
   PubMed Web of Science ®Google Scholar
• Boivin G. P., O'Toole B. A., Ormsby I. E., Diebold R. J., Eis M. J., Doetschman T., Kier A. B. Onset and progression of pathological lesions in transforming growth factor-β1-deficient mice. Am. J. Pathol. 1995; 146: 276–288
   PubMedGoogle Scholar
• Letterio J. J., Geiser A. G., Kulkarni A. B., Dang H., Kong L., Nakabayashi T., Mackall C. L., Gress R. E., Roberts A. B. Autoimmunity associated with TGF-β1 deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 1996; 98: 2109–2119
   PubMed Web of Science ®Google Scholar
• Shull M. M., Ormsby I., Kier A. B., Pawlowski S., Diebold R. J., Yin M., Allen R., Sidman C., Proetzel B., Calvin D., Annunziata N., Doetschman T. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693–699
   PubMed Web of Science ®Google Scholar
• Shull M. M., Kier A. B., Diebold R. J., Yin M., Doetschman T. The importance of transforming growth factor β1 in immunological homeostasis, as revealed by gene ablation in mice. Overexpression and knockout of cytokines in transgenic mice. Academic Press, London 1994; 135–159
   Google Scholar
• McCartney-Francis N. L., Mizel D. E., Redman R. S., Frazier-Jessen M., Panek R B, Kulkarni A. B., Ward J. M., McCarthy J. B., Wahl S. M. Autoimmune Sjägren's-like lesions in salivary glands of TGF-β1-deficient mice are inhibited by adhesion-blocking peptides. J. Immunol. 1996; 157: 1306–1312
   PubMed Web of Science ®Google Scholar
• Borkowski T. A., Letterio J. J., Farr A. G., Udey M. C. A role for endogenous transforming growth factor β1 in Langerhans cell biology: the skin of transforming growth factor β1 null mice is devoid of epidermal Langerhans cells. J. Exp. Med. 1996; 184: 2417–2422
   PubMed Web of Science ®Google Scholar
• Arsura M., Wu M., Sonenshein G. E. TGF-β1 inhibits NF-kB/Rel activity inducing apoptosis of B cells: transcriptional activation of IkBα. Immunity 1996; 5: 31–40
   PubMed Web of Science ®Google Scholar
• Wahl S. M. Transforming growth factor β: the good, the bad, and the ugly. J. Exp. Med. 1994; 180: 1587–1590
   PubMed Web of Science ®Google Scholar
• Wahl S. M., Hunt D. A., Wakefield L., McCartney-Francis N., Wahl L. M., Roberts A. B., Sporn M. B. Transforming growth factor beta (TGF-β) induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA 1987; 84: 5788–5792
   PubMed Web of Science ®Google Scholar
• Wahl S. M., Allen J. B., Weeks B. S., Wong H. L., Klotman P. E. Transforming growth factor β enhances integrin expression and type IV collagenase secretion in human monocytes. Proc. Natl. Acad. Sci. USA 1993; 90: 4577–4581
   PubMed Web of Science ®Google Scholar
• Brandes M. E., Wakefield L. M., Wahl S. M. Modulation of monocyte type I TGF-β receptors by inflammatory stimuli. J. Biol. Chem. 1991; 266: 19697–19703
   PubMed Web of Science ®Google Scholar
• Kulkarni A. B., Huh C. H., Becker D., Geiser A., Lyght M., Flanders K. C., Roberts A. B., Sporn M. B., Ward J. M., Karlsson S. Transforming growth factor-β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 1993; 90: 770–774
   PubMed Web of Science ®Google Scholar
• Kulkarni A. B., Ward J. M., Yaswen L., Mackali C. L., Bauer S. R., Huh C. G., Gress R. E., Karlsson S. Transforming growth factor-β1 null mice. An animal model for inflammatory disorders. Am. J. Pathol. 1995; 146: 1–12
   PubMedGoogle Scholar
• McCartney-Francis N. L., Mizel D. E., Frazier-Jessen M., Kulkarni A. B., McCarthy J. B., Wahl S. M. Lacrimal gland inflammation is responsible for ocular pathology in TGF-β1 null mice, Submitted
   Google Scholar
• Dang H., Geiser A. G., Letterio J. J., Nakabayashi T., Kong L., Fernandes G., Talal N. SLE-like autoantibodies and Sjögren's syndrome-like lymphoproli-feration in TGF-β knockout mice. J. Immunol. 1995; 155: 3205–3212
   PubMed Web of Science ®Google Scholar
• Yaswen L., Kulkarni A. B., Fredrickson T., Mittleman B., Schiffmann R., Payne S., Longenecker G., Mozes E., Karlsson S. Autoimmune manifestations in the transforming growth factor-β1 knockout mouse. Blood 1996; 87: 1439–1445
   PubMed Web of Science ®Google Scholar
• Geiser A. G., Letterio J. J., Kulkarni A. B., Karlsson S., Roberts A. B., Sporn M. B. TGF-β1 controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatability antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype. Proc. Natl. Acad. Sci. USA 1993; 90: 9944–9948
   PubMed Web of Science ®Google Scholar
• Frazier-Jessen M., McCartney-Francis N., Wahl S. M. Transforming growth factor-β: a cytokine paradigm. Handbook of Immune Modulating Agents, T. Kresina. Marcel Dekker, New York 1997, in press
   Google Scholar
• Stavnezer J. Regulation of antibody production and class scitching by TGF-β. J. Immunol. 1995; 155: 1647–1651
   PubMed Web of Science ®Google Scholar
• Hines K. L., Kulkarni A. B., McCarthy J. B., Tien H., Ward J. M., Christ M., McCartney-Francis N. L., Furcht L. T., Karlsson S., Wahl S. M. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in TGF-β1 knockout mice. Proc. Natl. Acad. Sci. USA 1994; 91: 5187–5191
   PubMed Web of Science ®Google Scholar
• Mossman T. R., Sad S. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol. Today 1996; 17: 138–146
   PubMedGoogle Scholar
• Nicholson L. B., Kuchroo V. K. Manipulation of the Th1/Th2 balance in autoimmune disease. Curr. Opin. Immunol. 1996; 8: 837–842
   PubMed Web of Science ®Google Scholar
• Powrie F., Carlino J., Leach M. W., Mauze S., Coffman R. L. A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RBlow CD4+ T cells. J. Exp. Med. 1996; 183: 2669–2674
   PubMed Web of Science ®Google Scholar
• Shimada A., Rohane P., Fathman C. G., Charlton B. Pathogenic and protective roles of CD45RBlow CD4+ cells correlate with cytokine profiles in the spontaneously autoimmune diabetic mouse. Diabetes 1996; 45: 71–78
   PubMed Web of Science ®Google Scholar
• Vodovotz Y., Bogdan C. Control of nitric oxide synthase expression by transforming growth factor-β: implications for homeostasis. Prog. Growth Factors Res. 1994; 5: 341–351
   PubMedGoogle Scholar
• Vodovotz Y., Geiser A. G., Chesler L., Letterio J. J., Campbell A., Lucia M. S., Sporn M. B., Roberts A. B. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor β1 null mouse. J. Exp. Med. 1996; 183: 2337–2342
   PubMedGoogle Scholar
• McCallion R. L., Ferguson M. W.J. Fetal wound healing and the development of antiscarring therapies for adult wound healing. The Molecular and Cellular Biology of Wound Repair, R AF. Clark. Plenum Press, New York 1996; 561–600
   Google Scholar
• Frank S., Madlener M., Werner S. Transforming growth factors β1, β2, and β3 and their receptors are differentially regulated during normal and impaired wound healing. J. Biol. Chem. 1996; 271: 10188–10193
   PubMed Web of Science ®Google Scholar
• Brown R. L., Ormsby I., Doetschman T. C., Greenhalgh D. G. Wound healing in the transforming growth factor-β1-deficient mouse. Wound Rep. Reg. 1995; 3: 25–36
   PubMedGoogle Scholar
• Letterio J. J., Roberts A. B. Transforming growth factor-β1-deficient mice: identification of isoform-specific activities in vivo. J. Leuk. Biol. 1996; 59: 769–774
   PubMed Web of Science ®Google Scholar
• Border W. A., Noble N. A. Transforming growth factor β in tissue fibrosis. N. Eng. J. Med. 1994; 331: 1286–1292
   PubMed Web of Science ®Google Scholar
• Kopp J. B., Factor V. M., Mozes M., Nagy P., Sanderson N., Bättinger E. P., Klotman P. E., Thorgeirsson S. S. Transgenic mice with increased plasma levels of TGF-β1 develop progressive renal disease. Lab. Invest. 1996; 74: 991–1003
   PubMed Web of Science ®Google Scholar
• Wahl S. M., Frazier-Jessen M., Jin W. W., Kopp J. B., Sher A., Cheever A. W. Cytokine regulation of schistosome-induced granuloma and fibrosis. Kidney Int. 1997; 51: 1370–1375
   PubMedGoogle Scholar
• Border W. A., Noble N. A., Yamamoto T., Harper J. R., Yamaguchi Y., Pierschbacher M. D., Ruoslahti E. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361–364
   PubMed Web of Science ®Google Scholar
• Isaka Y., Brees D. K., Ikegaya K., Kaneda Y., Imai E., Noble N. A., Border W. A. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. 1996; 2: 418–423
   PubMed Web of Science ®Google Scholar
• Imai E., Isaka Y., Akagi Y., Arai M., Moriyama T., Takenaka M., Kaneko T., Horio M., Ando A., Orita Y., Kaneda Y., Ueda N., Kamada T. Application of antisense oligodeoxynucleotides (ODNs) for the intervention of kidney disease. Cytokines, Growth Factors and Macrophages, H. Koide, I. Ichikawa. Karger, Basel 1996; 86–93
   Google Scholar
• Kitamura M., Burton S., English J., Kawachi H., Fine L. G. Transfer of a mutated gene encoding active transforming growth factor-β1 suppresses mitogenesis and IL-1 response in the glomerulus. Kidney Int. 1995; 48: 1747–1757
   PubMedGoogle Scholar
• Isaka Y., Fujiwara Y., Ueda N., Kaneda Y., Kamada T., Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-β or platelet-derived growth factor gene into the rat kidney. J. Clin. Invest. 1993; 92: 2597–2601
   PubMed Web of Science ®Google Scholar
• Choi B. M., Kwak H. J., Jun C. D., Park S. D., Kim K. Y., Kim H.-R., Chung H.-T. Control of scarring in adult wounds using antisense transforming growth factor-β1 oligodeoxynucleotides. Immunol. Cell Biol. 1996; 74: 144–150
   PubMed Web of Science ®Google Scholar
• Benn S. I., Whitsitt J. S., Broadley K. N., Nanney L. B., Perkins D., He L., Patel M., Morgan J. R., Swain W. F., Davidson J. M. Particle-mediated gene transfer with transforming growth factor-β1 cDNAs enhances wound repair in rat skin. J. Clin. Invest. 1996; 98: 2894–2902
   PubMed Web of Science ®Google Scholar
• Grainger D. J., Witchell C. M., Metcalfe J. C. Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nature Med. 1995; 1: 1067–1072
   PubMedGoogle Scholar
• Brandes M. E., Allen J. B., Ogawa Y., Wahl S. M. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J. Clin. Invest. 1991; 87: 1108–1113
   PubMed Web of Science ®Google Scholar
• Weiner H. L. Oral tolerance. Proc. Natl. Acad. Sci. USA 1994; 91: 10762–10765
   PubMedGoogle Scholar
• Chen Y., Kuchroo V. K., Inobe J. I., Hafler D. A., Weiner H. L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994; 265: 1237–1240
   PubMed Web of Science ®Google Scholar
• Weiner H. L., Mackin G. A., Matsui M., Orav E. J., Khoury S. J., Dawson D. M., Hafler D. A. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993; 259: 1321–1324
   PubMed Web of Science ®Google Scholar
• Trentham D. E., Dynesius-Trentham R. A., Orav E. J., Combitchi D., Lorenzo C., Sewall K. L., Hafler D. A., Weiner H. L. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993; 261: 1727–1730
   PubMed Web of Science ®Google Scholar
• McFarland H. F. Complexities in the treatment of autoimmune disease. Science 1996; 274: 2037–2038
   PubMed Web of Science ®Google Scholar
• Fakhrai H., Dorigo O., Shawler D. L., Lin H., Mercola D., Black K. L., Royston I., Sobol R. E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 1996; 93: 2909–2914
   PubMed Web of Science ®Google Scholar
• Grainger D. J., Metcalfe J. C. Tamoxifen: teaching an old drug new tricks. Nature Med. 1996; 2: 381–385
   PubMed Web of Science ®Google Scholar